Scynexis Advances ADPKD Drug SCY-770 into Phase 1 with $71M Cash Runway
Event summary
- Scynexis initiated a Phase 1 study of SCY-770, an AMPK activator for ADPKD, with topline data expected in Q3 2026.
- Phase 2 proof-of-concept study for SCY-770 in ADPKD patients planned for Q4 2026 initiation, with early efficacy readout in H2 2027.
- Completed dosing in Phase 1 IV formulation study of antifungal SCY-247, topline data on track for Q3 2026.
- Ended Q2 2026 with $71.1M in cash, cash equivalents, and investments, supporting operations into 2029.
The big picture
Scynexis is advancing its pipeline in rare diseases, with SCY-770 targeting ADPKD, a condition affecting 140,000 patients in the U.S. The company's strong cash position provides runway into 2029, while GSK's potential relaunch of BREXAFEMME could unlock additional revenue streams. The strategic focus on non-dilutive funding for SCY-247 highlights a balanced approach to financial and clinical milestones.
What we're watching
- Clinical Progress
- Whether SCY-770's Phase 1 data will support dose selection for the planned Phase 2 study.
- Financial Strategy
- How Scynexis will allocate its $71.1M cash position to advance its pipeline through 2029.
- Partnership Dynamics
- The pace at which GSK progresses with the relaunch of BREXAFEMME and potential milestone payments to Scynexis.
Related topics